Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment?
- PMID: 26634417
- PMCID: PMC5063125
- DOI: 10.1002/ejhf.452
Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment?
Comment on
-
Hyperkalaemia in heart failure: binding the patient to improved treatment?Eur J Heart Fail. 2015 Oct;17(10):997-9. doi: 10.1002/ejhf.404. Epub 2015 Oct 7. Eur J Heart Fail. 2015. PMID: 26443125 No abstract available.
-
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.Eur J Heart Fail. 2015 Oct;17(10):1057-65. doi: 10.1002/ejhf.402. Epub 2015 Oct 12. Eur J Heart Fail. 2015. PMID: 26459796 Free PMC article.
References
-
- Konstam MA. Hyperkalaemia in heart failure: binding the patient to improved treatment? Eur J Heart Fail 2015;17:997–999. - PubMed
-
- Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ‐Schmidt H, Berman L, Weir MR. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 2015;17:1057–1065. - PMC - PubMed
-
- Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ‐Schmidt H, Berman L, Pitt B, OPAL‐HK Investigators. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015;372:211–221. - PubMed
-
- Pitt B, Collins AJ, Reaven N, Funk S, Bakris GL, Bushinsky DA. Effect of cardiovascular comorbidities on the mortality risk associated with serum potassium. Circulation 2014;130(Suppl 2):A13320.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
